| Stereochemistry | ACHIRAL |
| Molecular Formula | C12H14N2O3 |
| Molecular Weight | 234.2512 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC2=C(NC(C)=C2CC(=O)NO)C=C1
InChI
InChIKey=VXMGLMHPFWGAJO-UHFFFAOYSA-N
InChI=1S/C12H14N2O3/c1-7-9(6-12(15)14-16)10-5-8(17-2)3-4-11(10)13-7/h3-5,13,16H,6H2,1-2H3,(H,14,15)
| Molecular Formula | C12H14N2O3 |
| Molecular Weight | 234.2512 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Deboxamet is a synthetic drug with anti-ulcer and anti-secretory activity, discovered by the Italian Istituto Biologico Chemioterapico ABC, S.p.A. The compound is claimed to have high anti-inflammatory action, as evidenced by the results of the tests of acute and chronic experimental phlogosis. Deboxamet demonstrated cytoprotective activity in a model of rat gastric mucosa necrosis. The cytoprotective effect of deboxamet is mediated by the rise of the availability of prostacyclins in the rat gastric mucosa.
